<qa>  How many adult subjects will be enrolled in the Phase II trial?This is a single-center, single-arm Phase II trial to assess the feasibility of dose-dense adjuvant chemotherapy in subjects with early stage I-III, HER-2 normal breast cancer. A total of 80 adult subjects will be enrolled in order to have 73 subjects who start the eribulin portion of the adjuvant study regimen. After completion of 4 cycles of AC, each subject will begin 4 cycles of eribulin mesylate 1.4 mgm2 intravenously over 2 to 5 minutes on Days 1 and 8 of every 21 day cycle. 